Pancragen

Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson class of bioregulatory peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is designed to target pancreatic tissue, particularly the endocrine pancreas (islets of Langerhans), through proposed peptide-DNA interactions that modulate gene expression in pancreatic cells. The Khavinson bioregulatory model proposes that Pancragen influences transcription of genes involved in beta cell function, insulin synthesis, and pancreatic tissue homeostasis. Pancragen has been investigated in Russian biogerontology research examining age-related changes in pancreatic function, glucose metabolism markers, and islet cell gene expression. It is part of the organ-specific tetrapeptide family within the Khavinson bioregulator system, alongside compounds targeting cardiac, hepatic, pulmonary, and other tissues.

Pancragen has been investigated for its proposed interactions with gene regulatory regions in pancreatic cells. The Khavinson model proposes that the Lys-Glu-Asp-Trp sequence penetrates cell membranes and interacts with DNA in promoter regions of pancreas-expressed genes, including those involved in insulin synthesis, beta cell proliferation, and islet cell maintenance. Researchers from the Saint Petersburg group observed that Pancragen treatment in pancreatic cell culture models was associated with changes in insulin gene expression and beta cell differentiation markers. Studies suggest that the peptide may influence the balance between beta cell maintenance and senescence in aging models. The tryptophan residue in Pancragen’s sequence contributes to its proposed DNA-binding properties, as indole-containing amino acids can intercalate with nucleic acid bases. These effects are attributed to direct peptide-DNA interactions and epigenetic modulation rather than conventional receptor signaling.

Pancreatic Function

Khavinson et al. (2008) investigated Pancragen in pancreatic cell models and observed changes in insulin gene expression and beta cell differentiation markers following treatment [1].

Bioregulatory Peptide Model

Khavinson VK (2002) described the comprehensive framework for tissue-specific bioregulatory peptides including those targeting the endocrine pancreas [2].

Aging and Pancreatic Function

Khavinson et al. (2012) reviewed the effects of bioregulatory peptides on age-related changes in endocrine function, including pancreatic tissue biology [3].